Genzyme Corp.  (GENZ) Trade Now »     Rate GENZ  -  Discuss GENZ  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

GENZ Analysis & Videos »


GENZ: Bull or Bear?

ETFI Global Healthcare Sector PerformIdex GENZ

76%

-7.09% in 14 days ETFI Global Healthcare Sector PerformIdex The accompanying table presents the top six rated companies with market caps of at least $250 million (USD) from each of the eight ETFI healthcare indexes (which include a database of about 320 companies) as equally-weighted components in the ETFI Global Healthcare Sector PerformIdex of 48 companies. 1.) ETFI Global Hospitals 2.) ETFI New Drug Regulatory Catalyst 3.) ETFI Global AnimalBiz 4.) ETFI Health Benefit Providers 5.) ETFI Cosmetic & Reconstructive Medicine 6.) ETFI G ... Continue reading »

By  Mike Havrilla   (-6.40%  risk: moderate)  11/08/08

Comment

Cosmetic & Reconstructive Medicine Companies Outpace the Healthcare Sector GENZ

76%

-1.18% in 7 days (closed on 11/08/08) Cosmetic & Reconstructive Medicine Companies Outpace the Healthcare Sector The accompanying table presents the statistics and seven highest rated companies from the ETFI Global Cosmetic and Reconstructive Medicine [CRM] Index, which includes companies with market caps over $100M engaged in prescription skin care treatments, weight loss, cosmetic medicine, regenerative medicine, orthopedic repair, and joint replacements. Over the past year, the CRM Index fared better than the Healthcare Sector SPDR (XLV) and the S&P 500 SPDR (SPY) for the top 30 rated companies a ... Continue reading »

By  Mike Havrilla   (-6.40%  risk: moderate)  11/01/08

Comment

FDA Action Heats Up Before Year-End GENZ

76%

+10.15% in 11 days (closed on 11/01/08) FDA Action Heats Up Before Year-End The accompanying table presents an updated calendar of expected FDA decision dates and advisory committee [FDAC] meetings expected to impact the price of underlying biotech and pharma stocks. Genzyme (GENZ) faces a FDAC tomorrow (10/21) for its pending BLA for Myozyme manufactured at the 2,000L bioreactor scale. Also, Discovery Labs (DSCO) submitted its complete response to the FDA last Friday to address an approvable ruling for Surfaxin back in May and insiders continue to buy the stock. DSCO expects the FDA to rule on Surfaxin ... Continue reading »

By  Mike Havrilla   (-6.40%  risk: moderate)  10/21/08

Comment

GENZ $89 Target Price...Undervalued by Both Projected P/E and PEG...Analysis Here GENZ

71%

-12.42% in 49 days GENZ is undervalued, looking only at valuation relative to its Industry average valuations. * GENZ has a Projected P/E of 16.40 * GENZ's Industry (Biotechnology) has an average Projected P/E of 19.09 * Implies a Projected Stock Price of $89.34 * GENZ has a projected earnings growth rate of 15.62% * GENZ has a PEG of 1.05 * GENZ's Industry (Biotechnology) has an average Projected PEG of 1.23 * Implies a Projected Stock Price of $89.93 Source of the analysis and calculations: http://www.freestockvalueranker.com/?method=peg_pe&symbol... ... Continue reading »

By  energycurve   (-11.23%  risk: moderate)  10/04/08

1 comment

Genzyme Corp. GENZ

69%

-13.92% in 132 days Analysts'  Recommendation: Buy       30 Days Ago: Buy     Analysts' Target: $81 Analysts' Targets  Deutsche Bank Securities $73    ... Continue reading »

By  Marian Filo   (-36.63%  risk: aggressive)  07/13/08

Comment

Lazard Sees Strong Growth for Genzyme GENZ

-11.45% in 231 days 4/4 - "A Lazard Capital Markets analyst said Friday it expects Genzyme Corp.'s earnings to grow 17 percent between 2008 and 2011, a rate second only to Celgene Corp. among its large-cap biotech peers...Analyst Matthew Osborne backed a "Buy" rating and $90 price target on Genzyme, saying the company's evolution into a well-diversified, profitable biotechnology company is the result of an aggressive 'growth through acquisition' strategy." "In a note to clients, Osborne projected stable growth of 13 percent to 14 percent for Genzyme's lead therapeutic division targeting rare genetic diseases,... Continue reading »

By  Matthew Osborne (Lazard Capital)   (-11.72%  risk: moderate)  04/05/08

Comment

Bullish on GENZ ... GENZ

64%

+3.08% in 7 days (closed on 01/31/08) Bullish "Mojo Crossover"! Get on the list for our "Hot Conference" chat room and trade with Mojo and 100 fellow traders coming soon (1st 100)! Just send an email (Subject: Hot Conference) http://modj97-predictwallstreet.blogspot.com The blog has updated charts for today's trading too. Continue reading »

By  Mr Mojo   (-2.93%  risk: conservative)  01/24/08

Comment

Genzyme (GENZ) stock breaks out on good news GENZ

57%

-8.07% in 352 days Genzyme ( GENZ ) saw its shares break out last week from $62.5 to over $68 on higher than average volume. The weekly chart below demonstrates this movement and its significance as it broke a long term trend of lower highs that started in 2005. This move was catalyzed by the O ctober 4 th vote by Bioenvision shareholders to decide the fate of the sale of the company to Genzyme . In addition, on Friday, Genzyme announced approval of Elaprase , its enzyme replacement therapy to treat Hunter syndrome. The company is seekin... Continue reading »

By  jmho   (-39.14%  risk: aggressive)  12/06/07

Comment

People Bullish on GENZ

Mike Havrilla Principal 76% 13 days ago	webmom Analyst 80% 24 days ago	decisionplan Associate 78% about 1 mo ago
energycurve Associate 71% about 1 mo ago	doc333 Analyst 69% about 1 mo ago

People Bearish on GENZ

Trade GENZ Now
and Get 30 Free Trades »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.